{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T23:09:52Z","timestamp":1778800192968,"version":"3.51.4"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,8,1]],"date-time":"2022-08-01T00:00:00Z","timestamp":1659312000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,7]],"date-time":"2022-07-07T00:00:00Z","timestamp":1657152000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000053","name":"NEI","doi-asserted-by":"publisher","award":["\/NEI P30 EY002162"],"award-info":[{"award-number":["\/NEI P30 EY002162"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","award":["P30 EY01583-26"],"award-info":[{"award-number":["P30 EY01583-26"]}],"id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008069","name":"University of California, San Francisco","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaapos.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"published-print":{"date-parts":[[2022,8]]},"DOI":"10.1016\/j.jaapos.2022.05.001","type":"journal-article","created":{"date-parts":[[2022,7,8]],"date-time":"2022-07-08T11:59:07Z","timestamp":1657281547000},"page":"187.e1-187.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Ocular examinations, findings, and toxicity in children taking vigabatrin"],"prefix":"10.1016","volume":"26","author":[{"given":"Yvette","family":"Schein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith D.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinxi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra G.","family":"de Alba Campomanes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gil","family":"Binenbaum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3945-2077","authenticated-orcid":false,"given":"Julius T.","family":"Oatts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaapos.2022.05.001_bib1","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.314.7075.180","article-title":"Severe persistent visual field constriction associated with vigabatrin","volume":"314","author":"Eke","year":"1997","journal-title":"BMJ"},{"key":"10.1016\/j.jaapos.2022.05.001_bib2","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1528-1157.2001.28600.x","article-title":"Vigabatrin visual toxicity: evolution and dose dependence","volume":"42","author":"Malmgren","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaapos.2022.05.001_bib3","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1016\/j.ophtha.2004.03.036","article-title":"Characteristic retinal atrophy with secondary \u201cinverse\u201d optic atrophy identifies vigabatrin toxicity in children","volume":"111","author":"Buncic","year":"2004","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.05.001_bib4","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1136\/adc.85.6.469","article-title":"Vigabatrin associated retinal dysfunction in children with epilepsy","volume":"85","author":"Koul","year":"2001","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaapos.2022.05.001_bib5","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1212\/WNL.50.3.614","article-title":"Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings","volume":"50","author":"Krauss","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.jaapos.2022.05.001_bib6","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1136\/jnnp.67.6.716","article-title":"Visual field defects associated with vigabatrin therapy","volume":"67","author":"Lawden","year":"1999","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jaapos.2022.05.001_bib7","first-page":"CD001770","article-title":"Treatment of infantile spasms","volume":"6","author":"Hancock","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaapos.2022.05.001_bib8","first-page":"274.e1","article-title":"Prevalence of visual impairment, ocular pathology, and ability to achieve a thorough examination in an eye clinic for patients with disabilities","volume":"23","author":"Menacker","year":"2019","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2022.05.001_bib12","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1016\/j.jcjo.2019.10.014","article-title":"Clinical implications and cost of electroretinography screening for vigabatrin toxicity","volume":"55","author":"Jastrzembski","year":"2020","journal-title":"Can J Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.05.001_bib13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1097\/WNO.0000000000000609","article-title":"Vigabatrin: lessons learned from the United States experience","volume":"38","author":"Foroozan","year":"2018","journal-title":"J\u00a0Neuro-Ophthalmol Off J North Am Neuro-Ophthalmol Soc"},{"key":"10.1016\/j.jaapos.2022.05.001_bib14","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1016\/S0161-6420(99)90345-7","article-title":"Symptomatic and asymptomatic visual loss in patients taking vigabatrin","volume":"106","author":"Daneshvar","year":"1999","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.05.001_bib15","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1111\/j.1528-1167.2008.01961.x","article-title":"Visual fields at school-age in children treated with vigabatrin in infancy","volume":"50","author":"Gaily","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaapos.2022.05.001_bib16","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1542\/peds.106.4.838","article-title":"Visual field constriction in children with epilepsy on vigabatrin treatment","volume":"106","author":"Iannetti","year":"2000","journal-title":"Pediatrics"},{"key":"10.1016\/j.jaapos.2022.05.001_bib17","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1212\/WNL.53.5.922","article-title":"Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects","volume":"53","author":"K\u00e4lvi\u00e4inen","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.jaapos.2022.05.001_bib18","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1111\/j.1528-1167.2010.02772.x","article-title":"Prevalence of visual field loss following exposure to vigabatrin therapy: a systematic review","volume":"51","author":"Maguire","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.jaapos.2022.05.001_bib19","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/dmcn.12573","article-title":"Does vigabatrin treatment for infantile spasms cause visual field defects? An international multicentre study","volume":"57","author":"Riikonen","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.jaapos.2022.05.001_bib20","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1046\/j.1528-1157.2002.17801.x","article-title":"Visual field constriction in 91 Finnish children treated with vigabatrin","volume":"43","author":"Vanhatalo","year":"2002","journal-title":"Epilepsia"},{"issue":"Pt A","key":"10.1016\/j.jaapos.2022.05.001_bib21","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.yebeh.2016.01.012","article-title":"A\u00a0lack of clinically apparent vision loss among patients treated with vigabatrin with infantile spasms: The UCLA experience","volume":"57","author":"Schwarz","year":"2016","journal-title":"Epilepsy Behav EB"},{"key":"10.1016\/j.jaapos.2022.05.001_bib22","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1212\/WNL.0000000000001069","article-title":"Vigabatrin retinal toxicity in children with infantile spasms: An observational cohort study","volume":"83","author":"Westall","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.jaapos.2022.05.001_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1034\/j.1600-0420.2003.00125.x","article-title":"Characterization of vigabatrin-associated optic atrophy","volume":"81","author":"Fris\u00e9n","year":"2003","journal-title":"Acta Ophthalmol Scand"},{"key":"10.1016\/j.jaapos.2022.05.001_bib25","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1167\/iovs.05-0854","article-title":"Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer","volume":"47","author":"Wild","year":"2006","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.jaapos.2022.05.001_bib26","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1023\/B:DOOP.0000005338.51554.e3","article-title":"Longitudinal changes in photopic OPs occurring with vigabatrin treatment","volume":"107","author":"Morong","year":"2003","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.05.001_bib27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3928\/01913913-20210111-03","article-title":"Clinical utility of electroretinograms for evaluating vigabatrin toxicity in children","volume":"58","author":"Strong","year":"2021","journal-title":"J\u00a0Pediatr Ophthalmol Strabismus"},{"key":"10.1016\/j.jaapos.2022.05.001_bib28","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10633-012-9320-7","article-title":"Electroretinographic (ERG) responses in pediatric patients using vigabatrin","volume":"124","author":"Moskowitz","year":"2012","journal-title":"Doc Ophthalmol Adv Ophthalmol"},{"key":"10.1016\/j.jaapos.2022.05.001_bib29","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.ophtha.2012.05.009","article-title":"Patterns of peripapillary retinal nerve fiber layer thinning in vigabatrin-exposed individuals","volume":"119","author":"Clayton","year":"2012","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jaapos.2022.05.001_bib30","first-page":"136","article-title":"Optical coherence tomography to monitor vigabatrin toxicity in children","volume":"20","author":"Origlieri","year":"2016","journal-title":"J\u00a0AAPOS"},{"key":"10.1016\/j.jaapos.2022.05.001_bib23","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/pan.13390","article-title":"The impact of general anesthesia on child development and school performance: a population-based study","volume":"28","author":"Schneuer","year":"2018","journal-title":"Paediatr Anaesth"}],"container-title":["Journal of American Association for Pediatric Ophthalmology and Strabismus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853122001276?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1091853122001276?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T22:37:14Z","timestamp":1778798234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1091853122001276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["S1091853122001276"],"URL":"https:\/\/doi.org\/10.1016\/j.jaapos.2022.05.001","relation":{},"ISSN":["1091-8531"],"issn-type":[{"value":"1091-8531","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular examinations, findings, and toxicity in children taking vigabatrin","name":"articletitle","label":"Article Title"},{"value":"Journal of American Association for Pediatric Ophthalmology and Strabismus","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaapos.2022.05.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Inc. on behalf of American Association for Pediatric Ophthalmology and Strabismus.","name":"copyright","label":"Copyright"}]}}